A Phase III, Randomized, Double-Blind, Double Dummy, Multicenter Trial Comparing the Efficacy and Safety of 2 Doses of Daily Oral ONO 4641 (0.05 mg and 0.1 mg) versus Interferon-beta-1a 30 mcg IM Weekly in Subjects with Relapsing-Remitting Multiple Sclerosis

Trial Profile

A Phase III, Randomized, Double-Blind, Double Dummy, Multicenter Trial Comparing the Efficacy and Safety of 2 Doses of Daily Oral ONO 4641 (0.05 mg and 0.1 mg) versus Interferon-beta-1a 30 mcg IM Weekly in Subjects with Relapsing-Remitting Multiple Sclerosis

Discontinued
Phase of Trial: Phase III

Latest Information Update: 29 Dec 2014

At a glance

  • Drugs Ceralifimod (Primary) ; Interferon beta-1a
  • Indications Multiple sclerosis
  • Focus Registrational; Therapeutic Use
  • Sponsors Merck KGaA
  • Most Recent Events

    • 27 Dec 2014 Status changed from recruiting to discontinued, according to European Clinical Trials Database (EudraCT2013-002351-15) record.
    • 27 Dec 2014 Status changed from recruiting to discontinued, according to European Clinical Trials Database (EudraCT2013-002351-15) record.
    • 07 Apr 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top